RESEARCH PEPTIDE FUNDAMENTALS / MATRIX
Four Peptides, Four Different Evidence-To-Anecdote Ratios
How GHK-Cu, KPV, semaglutide, and tirzepatide stack up on what has actually been studied versus what is merely reported — mechanism, trial depth, regulatory status, and the one caution that matters most for each.
The short version
This page lines up GHK-Cu, KPV, semaglutide, and tirzepatide on the dimensions that matter most for reading peptide research honestly: what class of molecule each is, how much human evidence actually exists, how large and reliable the community-report record is, its regulatory standing, and the single caution worth remembering for each. The pattern is stark. Semaglutide and tirzepatide sit at one end with deep clinical trial programs and equally deep community-reporting records. GHK-Cu has real but modest human trials and online claims that outrun them. KPV sits at the other end entirely: no human trials, and correspondingly little honest anecdote either. None of this is medical advice, and no dose is recommended anywhere on this page.
The comparison matrix
| Dimension | GHK-Cu | KPV | Semaglutide | Tirzepatide |
|---|---|---|---|---|
| Peptide class | Copper-binding tripeptide | Melanocortin-derived anti-inflammatory tripeptide | GLP-1 receptor agonist (single incretin arm) | GIP/GLP-1 dual receptor agonist |
| Human evidence base | Small controlled skin and hair trials [1][3][4][5] | None — cell culture and animal colitis models only [6][7][8][9][10] | Large multi-thousand-participant RCTs across several indications [11][12][13][14][17] | Large RCTs including a head-to-head win over semaglutide [11][19][20][21] |
| Community report volume | High — large skincare-forum presence | Effectively none | Very high — millions of patients | High and growing quickly |
| Regulatory status | Legal topical cosmetic ingredient; systemic use unapproved | Research chemical only; no approved status anywhere | FDA-approved prescription medicine | FDA-approved prescription medicine |
| Key caution | Evidence is real but narrow; online claims run well ahead of it | No human safety or dosing data exists at all | GI intolerance and weight regain after stopping [15] | Gallbladder/biliary disease signal [19] |
Peptide class
The four compounds are not variations on a theme; they are three distinct categories that happen to get grouped together under the umbrella term "peptide." GHK-Cu is a copper-chelating tripeptide originally identified as an endogenous tissue-repair signal. KPV is a melanocortin-derived tripeptide studied for anti-inflammatory action in the gut. Semaglutide and tirzepatide are both engineered incretin mimetics — synthetic peptides built to activate gut-hormone receptors far longer than the natural hormones do — but semaglutide engages one receptor (GLP-1) while tirzepatide engages two (GIP and GLP-1). Knowing which category a compound falls into is the first step toward knowing what kind of evidence to expect for it.
Human evidence base
This is where the four genuinely separate. GHK-Cu has a handful of small, controlled human trials — a 45-person hair-growth study [3] and topical skin studies comparing it against vitamin C and retinoic acid [1][4] — real evidence, but narrow in scope and sample size. KPV has no human trials of any kind; its entire evidentiary record is cell-culture work and mouse models of colitis [6][7][8][9][10]. Semaglutide has the deepest evidence base on this desk: multiple trials spanning tens of thousands of participants across diabetes, weight management, cardiovascular disease, and kidney disease [11][12][13][14][17]. Tirzepatide's evidence base is smaller only because it is newer — it already includes a large obesity trial, a large diabetes trial, and the direct head-to-head win over semaglutide [11][19][20][21].
Community report volume
Community-reported experience tracks distribution, not scientific interest. GHK-Cu has a large skincare-forum and product-review presence because it is widely sold as a cosmetic ingredient, even though the underlying human trial base is small. KPV has essentially no genuine community record — it has never been a consumer product, so there is little honest lived experience to gather, whatever marketing copy exists online. Semaglutide has an enormous community record because it is an approved medicine taken by millions of people, and tirzepatide's is smaller only because it reached the market more recently — its community record is growing quickly and, on current evidence, tracking a similar shape to semaglutide's. In no case does volume of anecdote substitute for the published record; the two are reported separately throughout this site precisely because they answer different questions.
Regulatory and approval status
Topical Copper Tripeptide-1 (GHK-Cu) is a legal cosmetic ingredient in the US, EU, and UK; injectable or other systemic use is unapproved research chemistry with no established regulatory pathway. KPV has no approved drug or dietary-supplement status anywhere and is sold strictly as a laboratory research chemical. Semaglutide and tirzepatide are both FDA-approved prescription medicines, available only through a licensed provider — semaglutide across diabetes, weight management, cardiovascular risk reduction, and liver disease; tirzepatide across diabetes, weight management, and sleep apnea.
Key caution
Each compound carries a defining caveat worth remembering. For GHK-Cu, the honest evidence is real but modest, and the gap between what the trials show and what marketing claims is the single most important thing to keep in view. For KPV, the caution is structural: no human safety or dosing data exists at all, so any claim about how it behaves in a person is extrapolation from a mouse, not observation of one. For semaglutide, the standout clinical cautions are gastrointestinal intolerance during dose escalation and substantial weight regain after stopping treatment [15]. For tirzepatide, the standout signal across pooled trial data is an increased risk of gallbladder or biliary disease [19]. Read together, the pattern across this desk is simple: the more a compound has been studied in humans, the more precisely its risks — and its benefits — can actually be stated.